FCMA
ABBV icon

Foresight Capital Management Advisors’s AbbVie ABBV Stock Holding History

Foresight Capital Management Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,697
Closed -$2.24M – 88
2025
Q1 		$2.24M Buy
10,697
+301
+3% +$58.5K 1.39% 32
2024
Q4 		$1.85M Buy
10,396
+1,297
+14% +$238K 1.08% 36
2024
Q3 		$1.8M Buy
9,099
+1,237
+16% +$231K 1.07% 38
2024
Q2 		$1.35M Buy
+7,862
New +$1.3M 0.91% 36

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Foresight Capital Management Advisors's ABBV Position: Q2 2025 in Review

Foresight Capital Management Advisors sold out of AbbVie (ABBV) in Q2 2025, closing a stake of 10,697 shares — an estimated $2.24M sold.

Foresight Capital Management Advisors first reported a position in ABBV in Q2 2024 and held it in 4 quarters. The position peaked at $2.24M in Q1 2025. 3,780 funds tracked by Wall St. Rank hold ABBV as of Q2 2025.

  • Foresight Capital Management Advisors reported no remaining AbbVie position as of Q2 2025 after selling out during the quarter.
  • Foresight Capital Management Advisors sold 10,697 AbbVie shares in Q2 2025, an estimated $2.24M.
  • Foresight Capital Management Advisors first reported a position in AbbVie in Q2 2024 and held it in 4 quarters.
  • Foresight Capital Management Advisors's AbbVie position peaked at $2.24M in Q1 2025.
  • 3,780 funds tracked by Wall St. Rank held AbbVie as of Q2 2025.

Based on Foresight Capital Management Advisors's 13F filing for Q2 2025, filed 23 Jul 2025.